STOCK TITAN

OncoSec Medical Inc - ONCS STOCK NEWS

Welcome to our dedicated news page for OncoSec Medical (Ticker: ONCS), a resource for investors and traders seeking the latest updates and insights on OncoSec Medical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OncoSec Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OncoSec Medical's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.83%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.83%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.39%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.17%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.49%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.24%
Tags
none
OncoSec Medical Inc

Nasdaq:ONCS

ONCS Rankings

ONCS Stock Data

1.65M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Pennington

About ONCS

oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar